RTP Mobile Logo

5MJCASH2015/2

OVERVIEW OF ACTIVITY
Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

COCP15/2

OVERVIEW OF ACTIVITY
In 2015 in the United States alone it is estimated that 220,800 new cases of prostate cancer (PCa) will occur. With an estimated 27,540 deaths in 2015, PCa is the second-leading cause of cancer death in men. The disease has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PCa is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.

ASHMM15

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY

5MJCASH2015

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

5MJCASH2015/1

OVERVIEW OF ACTIVITY
Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

ASHNHL15

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY

YIRMultitumor14/CME

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

OVERVIEW OF ACTIVITY

GICU214

OVERVIEW OF ACTIVITY

BCUS1214

OVERVIEW OF ACTIVITY

COCP15/1

OVERVIEW OF ACTIVITY
Nearly one million men each year are newly diagnosed with prostate cancer (PCa), making it the fifth most common cancer in both sexes combined and the second most common among men worldwide. In 2014 in the United States alone it is estimated that the disease will culminate in 233,000 new cases and 29,480 deaths. As such, PCa has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PCa is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets relevant to the continuous delivery of quality cross-functional care.

ESMOBreast14

TARGET AUDIENCE
This activity is intended for medical, radiation and surgical oncologists and other healthcare professionals involved in the treatment of breast cancer.

ESMOProstate14

TARGET AUDIENCE
This activity is intended for medical oncologists, urologists and other healthcare professionals involved in the treatment of prostate cancer (PC).

COCMM14/1

OVERVIEW OF ACTIVITY

Hematologic Oncology Update, Issue 3, 2014

OVERVIEW OF ACTIVITY

BCU214

OVERVIEW OF ACTIVITY
Breast cancer continues to be one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. In order to offer optimal patient care — including the option of clinical trial participation — the practicing cancer clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists, hematologist-oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES